Trials / Completed
CompletedNCT05310422
Safety Study of Tivanisiran to Treat Dry Eye
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 301 (actual)
- Sponsor
- Sylentis, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tivanisiran sodium ophthalmic solution | 1 drop in the affected eye(s) once daily |
| DRUG | Vehicle ophthalmic solution | 1 drop in the affected eye(s) once daily |
Timeline
- Start date
- 2022-03-24
- Primary completion
- 2023-10-11
- Completion
- 2023-10-11
- First posted
- 2022-04-05
- Last updated
- 2024-02-20
Locations
25 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05310422. Inclusion in this directory is not an endorsement.